Michael Barbella, Managing Editor03.08.24
Henry Schein Inc. has appointed Carole T. Faig as an independent board director to serve until the company's 2024 Annual Meeting of Stockholders in May, when she is expected to stand for re-election.
Faig has extensive expertise in finance, audit, and public accounting and particular experience in the healthcare sector, including hospitals, health insurance, biotechnology, and medical device companies. Prior to retiring in July 2021 from her 38-year career at Ernst & Young LLP (EY), Faig served in several leadership roles, including U.S. Health Leader and West Region Health and Life Sciences Leader, where she was responsible for developing and driving EY’s strategy to grow its healthcare practice in a rapidly changing environment.
Faig earned a bachelor's degree in business administration/accounting from Sam Houston State University and is a certified public accountant.
“We are pleased to welcome Carole to our board. Her proven expertise in navigating the transformation of healthcare and her accounting experience will be valuable assets as we advance the strategic goals of the company. We expect Carole will bring new perspectives that will enhance the effectiveness of our board, and we look forward to her contributions to Henry Schein’s continued success,” Henry Schein Board Chairman/CEO Stanley M. Bergman said.
Faig is currently a board member at three companies, where she serves as the Audit Committee Chair: Cue Health, a Nasdaq-listed company, and Affinia Therapeutics and QuVa Pharma, private equity–backed private businesses. A champion for diversity, she served on EY's Gender Equity Task Force and was awarded EY’s Chairman’s Value Award and Americas Assurance Inclusive Leadership Award in recognition of her commitment to building an inclusive workplace.
“It is a pleasure to join the board of Henry Schein and be part of a team actively shaping the future of healthcare amidst a rapidly evolving health ecosystem,” Faig stated. “Henry Schein’s commitment to providing healthcare solutions and to be a trusted advisor and consultant to our customers is truly inspiring. I look forward to leveraging my expertise to support our continued growth and impact.”
Henry Schein Inc. is a solutions company for healthcare professionals powered by a network of people and technology. With approximately 24,000 Team Schein Members worldwide, the company's advisor network provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Its business, clinical, technology, and supply chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional healthcare clinics, as well as other alternate care sites. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein private-brand products in stock.
A FORTUNE 500 company and a member of the S&P 500 index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The company's sales reached $12.6 billion in 2022, and have grown 12.1% annually since Henry Schein went public in 1995.
Faig has extensive expertise in finance, audit, and public accounting and particular experience in the healthcare sector, including hospitals, health insurance, biotechnology, and medical device companies. Prior to retiring in July 2021 from her 38-year career at Ernst & Young LLP (EY), Faig served in several leadership roles, including U.S. Health Leader and West Region Health and Life Sciences Leader, where she was responsible for developing and driving EY’s strategy to grow its healthcare practice in a rapidly changing environment.
Faig earned a bachelor's degree in business administration/accounting from Sam Houston State University and is a certified public accountant.
“We are pleased to welcome Carole to our board. Her proven expertise in navigating the transformation of healthcare and her accounting experience will be valuable assets as we advance the strategic goals of the company. We expect Carole will bring new perspectives that will enhance the effectiveness of our board, and we look forward to her contributions to Henry Schein’s continued success,” Henry Schein Board Chairman/CEO Stanley M. Bergman said.
Faig is currently a board member at three companies, where she serves as the Audit Committee Chair: Cue Health, a Nasdaq-listed company, and Affinia Therapeutics and QuVa Pharma, private equity–backed private businesses. A champion for diversity, she served on EY's Gender Equity Task Force and was awarded EY’s Chairman’s Value Award and Americas Assurance Inclusive Leadership Award in recognition of her commitment to building an inclusive workplace.
“It is a pleasure to join the board of Henry Schein and be part of a team actively shaping the future of healthcare amidst a rapidly evolving health ecosystem,” Faig stated. “Henry Schein’s commitment to providing healthcare solutions and to be a trusted advisor and consultant to our customers is truly inspiring. I look forward to leveraging my expertise to support our continued growth and impact.”
Henry Schein Inc. is a solutions company for healthcare professionals powered by a network of people and technology. With approximately 24,000 Team Schein Members worldwide, the company's advisor network provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Its business, clinical, technology, and supply chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional healthcare clinics, as well as other alternate care sites. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein private-brand products in stock.
A FORTUNE 500 company and a member of the S&P 500 index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The company's sales reached $12.6 billion in 2022, and have grown 12.1% annually since Henry Schein went public in 1995.